Saturn V Capital Management LP
In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 15, 2026), Saturn V Capital Management LP reported 21 stock positions worth $552.2 million. Its top holding was Alumis (ALMS) at 12.8% of the portfolio, followed by Amylyx Pharmaceuticals (AMLX, 10.9%) and Abivax SA-ADR (ABVX, 10.9%). Compared with Q4 2025, it opened 4 new positions, sold out of 3, added to 10 and reduced 6. The biggest buy was Alumis (ALMS, shares +2%) and the biggest sale Abivax SA-ADR (ABVX, shares −16%).
- Most Recent 13F
- Q2 2026
- Location
- AUSTIN, TX
- CIK
- 0001964437
- Portfolio Value
- $552.2M (Q1 2026)
- SEC Filing
- 0001964437-26-000005 ↗ filed May 15, 2026
Holdings Value
Holdings 21 stocks · $552.2M
| ALMS Alumis Inc. | 12.77% | 3,202,075 | $70.5M | Add +2.1% |
| AMLX Amylyx Pharmaceuticals Inc. | 10.95% | 4,349,885 | $60.5M | Reduce -3.3% |
| ABVX Abivax SA-ADR | 10.94% | 542,696 | $60.4M | Reduce -16.4% |
| PCVX Vaxcyte Inc. | 8.68% | 824,532 | $47.9M | Add +3.2% |
| PHVS Pharvaris NV | 6.15% | 1,201,402 | $33.9M | Add +5.4% |
| IMMX Immix Biopharma Inc. | 6.09% | 3,693,585 | $33.6M | Add +23.1% |
| CELC Celcuity Inc. | 5.83% | 281,904 | $32.2M | Reduce -11.1% |
| JAZZ Jazz Pharmaceuticals PLC | 5.58% | 162,961 | $30.8M | Reduce -34.3% |
| IRON Disc Medicine Inc. | 5.21% | 449,926 | $28.8M | Add +50.8% |
| XFOR X4 Pharmaceuticals Inc. | 4.83% | 6,456,646 | $26.7M | Add +11.3% |
| COGT Cogent Biosciences Inc. | 4.37% | 626,635 | $24.1M | Reduce -48.5% |
| MNPR Monopar Therapeutics Inc. | 3.43% | 345,626 | $18.9M | Add +6.1% |
| DYN Dyne Therapeutics Inc. | 3.17% | 966,609 | $17.5M | Reduce -46.0% |
| IVVD Invivyd Inc. | 2.58% | 10,949,084 | $14.2M | Add +41.5% |
| CADL Candel Therapeutics Inc. | 2.57% | 2,896,588 | $14.2M | New |
| OCS Oculis Holding AG | 2.49% | 516,761 | $13.7M | No change |
| OVID Ovid Therapeutics Inc. | 1.68% | 4,166,666 | $9.2M | Add +66.7% |
| IKT Inhibikase Therapeutics Inc. | 1.18% | 3,863,445 | $6.5M | Add +0.2% |
| ZURA Zura Bio Ltd. | 0.80% | 739,960 | $4.4M | New |
| ANRO Alto Neuroscience Inc. | 0.36% | 88,999 | $2.0M | New |
| MSLE Satellos Bioscience Inc. | 0.36% | 350,000 | $2.0M | New |
Portfolio Sells Q4 2025 → Q1 2026
| ABVX Abivax SA-ADR | Reduce -16.4% | 10.94% | −5.12 |
| COGT Cogent Biosciences Inc. | Reduce -48.5% | 4.37% | −3.57 |
| OCUL Ocular Therapeutix Inc. | Sold out | 0.00% | −3.35 |
| DYN Dyne Therapeutics Inc. | Reduce -46.0% | 3.17% | −3.25 |
| JAZZ Jazz Pharmaceuticals PLC | Reduce -34.3% | 5.58% | −2.16 |
| CNTA Centessa Pharmaceuticals Ltd. | Sold out | 0.00% | −1.30 |
| IVA Inventiva SA - ADR | Sold out | 0.00% | −0.24 |
| CELC Celcuity Inc. | Reduce -11.1% | 5.83% | +0.02 |
| AMLX Amylyx Pharmaceuticals Inc. | Reduce -3.3% | 10.95% | +0.98 |
Portfolio Buys Q4 2025 → Q1 2026
| ALMS Alumis Inc. | Add +2.1% | 12.77% | +7.16 |
| IMMX Immix Biopharma Inc. | Add +23.1% | 6.09% | +3.21 |
| CADL Candel Therapeutics Inc. | New | 2.57% | +2.57 |
| PCVX Vaxcyte Inc. | Add +3.2% | 8.68% | +1.91 |
| OVID Ovid Therapeutics Inc. | Add +66.7% | 1.68% | +0.93 |
| IRON Disc Medicine Inc. | Add +50.8% | 5.21% | +0.86 |
| ZURA Zura Bio Ltd. | New | 0.80% | +0.80 |
| XFOR X4 Pharmaceuticals Inc. | Add +11.3% | 4.83% | +0.57 |
| ANRO Alto Neuroscience Inc. | New | 0.36% | +0.36 |
| MSLE Satellos Bioscience Inc. | New | 0.36% | +0.36 |
| PHVS Pharvaris NV | Add +5.4% | 6.15% | +0.34 |
| IKT Inhibikase Therapeutics Inc. | Add +0.2% | 1.18% | −0.28 |
| MNPR Monopar Therapeutics Inc. | Add +6.1% | 3.43% | −0.47 |
| IVVD Invivyd Inc. | Add +41.5% | 2.58% | −0.93 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 23 | $697.5M | AMLX, ALMS, ABVX, PCVX, IMMX |
| Q1 2026 | 21 | $552.2M | ALMS, AMLX, ABVX, PCVX, PHVS |
| Q4 2025 | 20 | $544.9M | ABVX, AMLX, COGT, JAZZ, PCVX |
| Q3 2025 | 17 | $456.0M | ABVX, AMLX, JAZZ, DYN, COGT |
| Q2 2025 | 24 | $246.8M | JAZZ, IRON, AMLX, PCVX, COGT |
| Q1 2025 | 21 | $198.2M | ASND, IRON, CGON, XENE, MRUS |
| Q4 2024 | 24 | $255.4M | IRON, ASND, MLTX, CGON, PCVX |
| Q3 2024 | 25 | $279.8M | ASND, IRON, PCVX, CGON, COGT |
| Q2 2024 | 26 | $264.6M | ARGX, IRON, CRNX, PCVX, ASND |
| Q1 2024 | 21 | $249.4M | CRNX, ARGX, CYTK, KALV, MRUS |